More interestingly, combining a cancer vaccine with L-pampoTM and anti-PD-L1 antibody bolstered robust CD8+ T-cell responses and enhanced anti-cancer efficacy, suggesting the possibility of overcoming low response rates and improving patients’ outcomes with cold tumor therapy. Here, CD8A is linked to cancer.